三元生物(301206.SZ):一季度淨利潤預增194.56%-271.40%
格隆匯4月1日丨三元生物(301206.SZ)公佈2024年第一季度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利2,300萬元—2,900萬元,比上年同期增長194.56%—271.40%;扣除非經常性損益後的淨利潤盈利2,250萬元—2,850萬元,比上年同期增長208.63%—290.94%。
2024年第一季度經營業績增長的主要原因,一是受益於下游客户訂單增加,公司主營產品銷量增加,產能利用率逐步上升。二是公司按照既定發展規劃,堅持以市場為主、客户為先銷售策略,積極開拓國際市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.